NEOGENOMICS INC — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: NEOGENOMICS INC (NEO)
CIK: 0001077183
Period of Report: 2021-03-02

Reporting Person: Weiss Lawrence Martin (Chief Medical Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-02	Common Stock	A	5276	—	Acquired	105797	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-02	Stock Option (Right to Buy)	$53.17	A	29895	Acquired	2028-03-02	Common Stock (29895.0)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$9.22	2023-04-19	Common Stock (6667.0)	6667	Direct
Stock Option (Right to Buy)	$13.87	2023-12-12	Common Stock (8334.0)	8334	Direct
Stock Option (Right to Buy)	$19.6	2024-03-01	Common Stock (27017.0)	27017	Direct
Stock Option (Right to Buy)	$28.33	2027-03-02	Common Stock (37514.0)	37514	Direct

Footnotes

F1: On April 19, 2018, Dr. Weiss was granted 20,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F2: On December 12, 2018, Dr. Weiss was granted 25,000 stock options. These options vest ratably over the first three anniversary dates of the grant date.

F3: On March 1, 2019, Dr. Weiss was granted 36,022 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F4: On March 2, 2020, Dr. Weiss was granted 37,514 stock options. These options vest ratably over the first four anniversary dates of the grant date.

F5: On March 2, 2021, Dr. Weiss was granted 29,895 stock options. These options vest ratably over the first four anniversary dates of the grant date.